degrader antibody conjugate

Johnson & Johnson to buy Firefly Bio for $1 billion to strengthen cancer pipeline

The acquisition brings Firefly Bio’s proprietary Firelink™ degrader antibody conjugate platform into Johnson & Johnson’s oncology portfolio, expanding its focus…